Paul McIntosh, MD
Neuromuscular Medicine · Philadelphia, PANPI 1821520412
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Amicus Therapeutics, Inc. accounts for 70.1% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $30,836, more than ten times the $27 reported in 2022.
Across 28 payments — averaging $1761.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amicus Therapeutics, Inc.$35K
- Sanofi$15K
- Takeda Pharmaceuticals U.S.A., Inc.$138
- Johnson & Johnson$18
What the payments were for
- Consulting fees$22,56346%
- Speaking & faculty fees$14,28229%
- Travel & lodging$12,01824%
- Food & beverage$4331%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amicus Therapeutics, Inc. | 18 | $34,585 |
| Sanofi | 7 | $14,572 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $138 |
| Johnson & Johnson | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- POMBILITI$9,246
- OPFOLDA$9,246
- NEXVIAZYME$124
- LUMIZYME$124
How this compares
Too few neuromuscular medicine providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvgartEfgartigimod Alfa-Fcab | 25 | $462,359 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 39 | $413,319 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 20 | $300,147 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 18 | $240,113 |
| Mycophenolate Mofetil | 27 | $5,054 |
| Pyridostigmine Bromide | 28 | $2,327 |
| Azathioprine | 18 | $1,348 |
| Gabapentin | 83 | $904 |
| Pregabalin | 13 | $427 |
| Prednisone | 60 | $393 |
| Sodium Chloride0.9 % Sodium Chloride | 59 | $254 |
| Duloxetine Hcl | 11 | $159 |
| Propranolol Hcl | 12 | $114 |
Paid to pharmacies, not to this prescriber.
Other neuromuscular medicine in Philadelphia
- Hristelina IlievaPhiladelphia$5K
- Sara DehbashiPhiladelphia$856
- Gema Giler-SacotoPhiladelphia$527
- Jessica YiPhiladelphia$340
- Rebecca HsuPhiladelphia$191
- Bradley TuckerPhiladelphia$112
- Michael BaerPhiladelphia$18
- Fang SunPittsburgh$2K
- Naaima MuftiEaston$629
- Connie TangAllentown$261
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.